Cypherpunk Technologies (NASDAQ:CYPH) Shares Cross Below Fifty Day Moving Average – Here’s What Happened

Shares of Cypherpunk Technologies (NASDAQ:CYPH) passed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $0.87 and traded as low as $0.6218. Cypherpunk Technologies shares last traded at $0.7160, with a volume of 4,142,837 shares changing hands.

Analyst Upgrades and Downgrades

CYPH has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of Cypherpunk Technologies from a “sell” rating to a “hold” rating in a research report on Tuesday, November 25th. Weiss Ratings restated a “sell (e+)” rating on shares of Cypherpunk Technologies in a report on Thursday, January 22nd. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Cypherpunk Technologies presently has a consensus rating of “Reduce”.

Cypherpunk Technologies Stock Up 16.4%

The business has a 50-day moving average price of $0.87 and a two-hundred day moving average price of $0.84. The company has a market capitalization of $29.67 million, a price-to-earnings ratio of -0.59 and a beta of -0.16.

Institutional Investors Weigh In On Cypherpunk Technologies

Several large investors have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd bought a new stake in shares of Cypherpunk Technologies in the fourth quarter valued at approximately $44,000. Millennium Management LLC bought a new stake in shares of Cypherpunk Technologies during the fourth quarter valued at about $37,000. State Street Corp purchased a new stake in shares of Cypherpunk Technologies in the fourth quarter worth about $163,000. LPL Financial LLC purchased a new stake in shares of Cypherpunk Technologies in the fourth quarter worth about $38,000. Finally, Geode Capital Management LLC bought a new position in shares of Cypherpunk Technologies in the fourth quarter valued at approximately $615,000. Hedge funds and other institutional investors own 30.46% of the company’s stock.

About Cypherpunk Technologies

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.